Hypomethylating Agents in Combination with Venetoclax as Frontline Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndromes; A Single Center Experience from Pakistan
Authors:
- 19 May 2025
- journal article
- research article
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 743-750
Abstract
The present study was done to determine the response and survival analysis in upfront hypomethylating agents-Venetoclax (HMA-Ven) regimen in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients unfit for chemotherapy. This cross sectional study was conducted at National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD-BMT), Karachi, Pakistan from January 2020 to December 2023. The primary endpoint was overall response rate (ORR) defined as Complete Remission (CR), Complete Count Recovery (CCR), Partial Count Recovery (PCR) with or without blasts. Secondary outcomes included median overall survival (OS) and event-free survival (FFS) analysed by Kaplan-Meier method. A total of 33 (22 AML and 11 MDS) patients were included. AML patients had median age of 62 and 48years was observed in MDS. After 4 cycles of HMA + Ven, ORR was reported as 93.7%. Median OS was 14 months, with deeper (CR vs. CCR; 20 vs. 14 months; p < 0.001) and quicker responses (achieved in 2 vs. 4 cycles; 14 vs. 11 months, p < 0.001) associated with improved OS. However, median EFS were 14 months. In MDS, ORR was 100%. Median OS and EFS were 11 and 10 months, respectively. Our study demonstrated the real-world applicability of HMA-Ven based regimen for unfit AML/MDS patients in low-middle income countries (LMIC) settings. Further national, multicentre, larger collaborative studies utilizing novel biomarkers are necessary to enhance risk assessment and treatment outcomes.Keywords
This publication has 24 references indexed in Scilit:
- Treatment challenges and outcomes of older patients with acute myeloid leukemia from IndiaAnnals of Hematology, 2024
- Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapySignal Transduction and Targeted Therapy, 2023
- Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic SyndromeClinical Hematology International, 2023
- Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community SettingClinical Lymphoma Myeloma and Leukemia, 2023
- Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 studyThe Lancet Haematology, 2022
- Real‐world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blastsAmerican Journal of Hematology, 2022
- Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapyJapanese Journal of Clinical Oncology, 2021
- Mayo Clinic experience with 1123 adults with acute myeloid leukemiaBlood Cancer Journal, 2021
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaLeukemia, 2019